End-of-day quote
Other stock markets
|
||
- | - |
07/05 | AstraZeneca target raised; Antofagasta lowered | AN |
01/05 | HSS Hire annual profit falls amid investment spending; CFO to depart | AN |
Sales 2024 * | 35Cr 44Cr 0 3.69TCr | Sales 2025 * | 36Cr 46Cr 0 3.82TCr | Capitalization | 6.06Cr 7.71Cr 0 643.79Cr |
---|---|---|---|---|---|
Net income 2024 * | 60L 76.29L - 64Cr | Net income 2025 * | 70L 89L - 74Cr | EV / Sales 2024 * | 0.45 x |
Net Debt 2024 * | 9.49Cr 12Cr 0 1.01TCr | Net Debt 2025 * | 9.95Cr 13Cr 0 1.06TCr | EV / Sales 2025 * | 0.44 x |
P/E ratio 2024 * |
9.77
x | P/E ratio 2025 * |
8.61
x | Employees | - |
Yield 2024 * |
6.71% | Yield 2025 * |
6.91% | Free-Float | 25.3% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Ashmore
CEO | Chief Executive Officer | 60 | 01/17/01 |
Paul Quested
DFI | Director of Finance/CFO | 54 | 01/16/01 |
Daniel Joll
BRD | Director/Board Member | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 09/15/09 | |
Director/Board Member | 71 | 09/15/09 | |
Alan Peterson
CHM | Chairman | 77 | 01/12/01 |
1st Jan change | Capi. | |
---|---|---|
+10.51% | 4.3TCr | |
+1.90% | 3.13TCr | |
+21.66% | 1.79TCr | |
-16.54% | 724.59Cr | |
+8.18% | 511.73Cr | |
-11.16% | 377.33Cr | |
-22.51% | 293.45Cr | |
-14.26% | 255.31Cr | |
+13.08% | 206.5Cr |